Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 600 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $30.38, for a total value of $18,228.00. Following the completion of the sale, the chief executive officer now directly owns 743,675 shares in the company, valued at approximately $22,592,846.50. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Shares of Atara Biotherapeutics Inc (NASDAQ ATRA) traded down $0.75 during midday trading on Thursday, hitting $27.50. The stock had a trading volume of 655,029 shares, compared to its average volume of 1,469,833. Atara Biotherapeutics Inc has a 1-year low of $11.80 and a 1-year high of $30.90. The firm has a market cap of $864.33, a price-to-earnings ratio of -7.93 and a beta of 1.27.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.05). research analysts anticipate that Atara Biotherapeutics Inc will post -4 earnings per share for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Neuberger Berman Group LLC raised its position in shares of Atara Biotherapeutics by 15.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company’s stock worth $18,454,000 after acquiring an additional 147,061 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Atara Biotherapeutics by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 845,877 shares of the biotechnology company’s stock worth $11,842,000 after acquiring an additional 13,952 shares in the last quarter. Artal Group S.A. raised its position in shares of Atara Biotherapeutics by 20.0% during the 3rd quarter. Artal Group S.A. now owns 600,000 shares of the biotechnology company’s stock worth $9,930,000 after acquiring an additional 100,000 shares in the last quarter. Northern Trust Corp raised its position in shares of Atara Biotherapeutics by 12.0% during the 2nd quarter. Northern Trust Corp now owns 298,739 shares of the biotechnology company’s stock worth $4,183,000 after acquiring an additional 32,065 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Atara Biotherapeutics by 4.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 125,713 shares of the biotechnology company’s stock worth $1,760,000 after acquiring an additional 5,616 shares in the last quarter. 69.67% of the stock is currently owned by institutional investors and hedge funds.

ATRA has been the topic of a number of analyst reports. BidaskClub raised Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Canaccord Genuity reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research report on Friday, December 29th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $20.00 price target on shares of Atara Biotherapeutics in a research report on Friday, October 6th. Jefferies Group reaffirmed a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a research report on Thursday, October 5th. Finally, Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target on the stock in a research report on Wednesday, January 3rd. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $26.00.

ILLEGAL ACTIVITY NOTICE: “Isaac E. Ciechanover Sells 600 Shares of Atara Biotherapeutics Inc (ATRA) Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/18/isaac-e-ciechanover-sells-600-shares-of-atara-biotherapeutics-inc-atra-stock.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.